-+ 0.00%
-+ 0.00%
-+ 0.00%

Racura Oncology Gets First Site Ethics Approval for Phase 2b/3 RC220 Leukemia Trial

PUBT·11/18/2026 12:39:04
Diffusion vocale
Racura Oncology Gets First Site Ethics Approval for Phase 2b/3 RC220 Leukemia Trial
  • Racura Oncology received Sheba Medical Center ethics clearance for its Phase 2b/3 EMILI trial of RC220 in relapsed or refractory acute myeloid leukemia.
  • First patient dosing is expected in the first quarter of 2027, following planned site activation by the end of 2026.
  • The trial will assess whether a single treatment course induces remission, enabling patients to proceed to stem cell transplantation.
  • Existing cash will fund Phase 2b, which is expected to take 18 to 24 months.
  • Progression to Phase 3 depends on Phase 2b results, additional funding and regulatory consultation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Racura Oncology Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611180737PR_NEWS_USPR_____CN01091) on November 18, 2026, and is solely responsible for the information contained therein.